Surveillance in Barrett's Esophagus : A Failed Premise
スポンサーリンク
概要
- 論文の詳細を見る
Background: It is recommended that patients in whom Barretts esophagus is diagnosed undergo surveillance endoscopy. However, multiple issues regarding the efficacy and feasibility of surveillance remain.Methods: Quantitative techniques were used to examine surveillance in patients with Barretts esophagus. A retrospective case-control study was performed to determine whether surveillance endoscopy prolonged survival in a cohort of U.S. veterans diagnosed with esophageal adenocarcinoma. Cost-effectiveness analysis was employed to compare competing strategies of management for patients with Barretts esophagus to determine whether surveillance strategies using alternative biomarkers could out-perform dysplasia based surveillance, and whether new techniques for eradicating Barretts metaplasia would constitute cost-effective strategies.Results: Surveillance did not improve long-term survival among veterans diagnosed with esophageal adenocarcinoma. Lead-time bias has confounded previous reports claiming the efficacy of endoscopic surveillance. Cost-effectiveness analysis revealed that while screening 50-year old Caucasian males with heartburn may be cost-effective, surveillance even at 5 year intervals among patients with Barretts esophagus without dysplasia exceeded the threshold of cost-effective care. If a biomarker were developed whose sensitivity and specificity to predict cancer development exceeded 80%, this could represent a more viable strategy than dysplasia-based surveillance and overcome the inherent inter- and intra-observer variations in dysplasia diagnosis that currently limit the effectiveness of surveillance programs. Finally, techniques that reduce cancer incidence such as endoscopic mucosal resection or ablation will likely be more cost-effective than current surveillance strategies that rely on early detection of cancer.Conclusions: Current recommendations for the management of patients with Barretts esophagus are flawed. Future guidelines should include alternative markers of cancer risk and focus on strategies that reduce cancer incidence instead of cancer detection.
- 2009-03-01
論文 | ランダム
- P2-182 ヒト子宮平滑筋における成体幹細胞の同定と単離(Group 138 生殖・子宮筋腫,子宮内膜症I,一般演題,講演要旨,第58回日本産科婦人科学会学術講演会)
- P1-290 新しい子宮内膜症モデルマウスの作成とそのリアルタイム解析システムの開発(Group 40 生殖・子宮筋腫,子宮内膜症V,一般演題,講演要旨,第58回日本産科婦人科学会学術講演会)
- 分泌期優位蛋白質glycodelinと子宮内膜腺上皮細胞の運動能
- 229 子宮内膜間質細胞の分化過程でアセチル化されるコアヒストンとその修飾部位の同定
- 323 ヒト子宮内膜間質細胞脱落膜化過程における接着斑分子の動態